Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 6/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4059108 | 0.82 | SYK (0.57) | SYKPOLBHTT | |
| SCHEMBL4058707 | 0.77 | SYK (0.56) | SYKPOLBHTT | |
| SCHEMBL4262049 | 0.77 | SYK (0.75) | SYK | |
| SCHEMBL4058627 | 0.76 | SYK (0.42) | SYKPOLBHTT | |
| SCHEMBL4060562 | 0.73 | IDO1 (0.42) | SYKHRH3 | |
| SCHEMBL4063418 | 0.73 | SYK (0.53) | SYKPOLBHTT | |
| SCHEMBL4066371 | 0.71 | SYK (0.42) | SYKPOLBHTT | |
| SCHEMBL4717608 | 0.68 | SYK (0.47) | SYKPOLB | |
| SCHEMBL4064998 | 0.68 | SYK (0.42) | SYKPOLB | |
| SCHEMBL4065544 | 0.67 | SYK (0.48) | SYKPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221599-A1 | PHTHALAZINONE PYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN-LA ROCHE, INC. | 2009-09-03 | — | — | US | disclosed |
| US-7501410-B2 | Methods of inhibiting BTK and SYK protein kinases | ROCHE PALO ALTO LLC (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1998777-A1 | METHODS OF INHIBITING BTK AND SYK PROTEIN KINASES | F. Hoffmann-La Roche AG (CH) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007107469-A1 | METHODS OF INHIBITING BTK AND SYK PROTEIN KINASES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-09-27 | — | — | WO | disclosed |
| US-20070219195-A1 | e.g. 4-(5-Methyl-2H-pyrazole-3-ylamino)-phenyl-2H-phthalazin-1-one2-Phenyl-2,3-dihydro-phthalazine-1,4-dione; tyrosine kinase inhibitor; antiinflammatory agent; asthma, rheumatoid arthritis, systemic lupus erythematosus or multiple sclerosis | ROCHE PALO ALTO LLC | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219195-A1 | e.g. 4-(5-Methyl-2H-pyrazole-3-ylamino)-phenyl-2H-phthalazin-1-one2-Phenyl-2,3-dihydro-phthalazine-1,4-dione; tyrosine kinase inhibitor; antiinflammatory agent; asthma, rheumatoid arthritis, systemic lupus erythematosus or multiple sclerosis | SYK, BTK, LCK | SYK 1/4885ADORA2A 4285/4885ADORA1 4527/4885 |
| US-20090221599-A1 | PHTHALAZINONE PYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | CYP3A5, CYP3A43, CYP51A1 | SYK 2689/4885ADORA2A 3046/4885ADORA1 2269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.